West Pharmaceutical renews crosslicense and distribution agreements with Daikyo for 10 years

WEST PHARMACEUTICAL SERVICES INC

West holds 49% ownership in Daikyo; new agreements effective July 14, 2026, replace 2017 agreements as amended.
Crosslicense covers joint development of closures, vials, cartridges, syringes, and medical device components.
West gets exclusive license from Daikyo outside Japan (with exceptions); Daikyo gets non-exclusive license from West.
West is exclusive distributor of Daikyo products outside Japan; Daikyo is non-exclusive distributor of West products in Japan.
Agreements are royalty-free except for a fixed royalty on certain patents; each has a 10-year term with change-of-control termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.